Is Bolt Biotherapeutics, Inc. (BOLT) a Buy, Sell, or Hold?
NASDAQ : BOLT
Bolt Biotherapeutics, Inc. — News
$3.98 USD
-$0.07 (-1.73%)
- Volume
- 10.33K
- Average Volume
- 25.24K
- Market Capitalization
- $7.65M
- P/E Ratio
- -0.25
- Dividend Yield
- 0.00%
- Price Target
- $4.00
- Year High
- $7.20
- Year Low
- $3.75
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.51
| Source | Headline |
|---|---|
|
Bolt Metals Announces Closing of Option to Acquire the High-Grade Floralia Iron Project
VANCOUVER, BC / ACCESS Newswire / June 12, 2026 / Bolt Metals Corp. ("Bolt" or the "Company") (CSE:BOLT)(OTCQB:PCRCF)(FSE:A3D8AK), is pleased to announce that, further to its press releases dated May 13, 2026, the letter of intent dated October 23, 2025, and the definitive option agreement dated May 12, 2026, as amended (the "Option Agreement"), with Max Iron Brazil Ltd. ("MaxIron"), an entity controlled by Max Resource Corp. ("Max"), pursuant to which Bolt has the right to acquire 100% of the Florália High Purity Iron Property (title no. accessnewswire.com - 2026-06-12 07:00:00 |
|
Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Lags Revenue Estimates
Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $4.31 per share versus the Zacks Consensus Estimate of a loss of $2.85. This compares to a loss of $5.8 per share a year ago. zacks.com - 2026-05-12 18:40:22 |
|
Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2026, and provided a business update. globenewswire.com - 2026-05-12 16:05:00 |
